Minoryx Therapeutics
Mataró, ES · 8 known investors
Minoryx is a registration-stage biotech company developing novel therapies for severe, orphan genetic diseases of the central nervous system, with a lead compound (leriglitazone) in clinical trials for conditions including cerebral adrenoleukodystrophy, Friedreich's Ataxia, and Rett syndrome.
Founders & leadership
MM
Marc MartinellinCo-Founder & Chief Executive Officer
Investors · 8
Chiesi VenturesBoston · $5M
Criteria Bio VenturesBarcelona
Fund+Leuven · $5.5M – $16.5M
Invivo Capital PartnersBarcelona · $2.2M – $4.3M
Kurma PartnersParis · $162K – $10.8M
Roche Venture FundBasel · $648K – $3.2M
Ysios CapitalBarcelona · $5.4M – $21.6M
Columbus Venture Partnersreported · 2 sourcesValenciavia Jose Mesa · inferred
In the news
Frequently asked questions
- What does Minoryx Therapeutics do?
- Minoryx is a registration-stage biotech company developing novel therapies for severe, orphan genetic diseases of the central nervous system, with a lead compound (leriglitazone) in clinical trials for conditions including cerebral adrenoleukodystrophy, Friedreich's Ataxia, and Rett syndrome.
- Who founded Minoryx Therapeutics?
- Minoryx Therapeutics was founded by Marc Martinell.
- Who are Minoryx Therapeutics's investors?
- Minoryx Therapeutics's investors include Chiesi Ventures, Criteria Bio Ventures, Fund+, Invivo Capital Partners, Kurma Partners, Roche Venture Fund, Ysios Capital, Columbus Venture Partners.
- Where is Minoryx Therapeutics headquartered?
- Minoryx Therapeutics is headquartered in Mataró, ES.